0000000000718716

AUTHOR

Aniruddha Choudhury

showing 2 related works from this author

Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor …

2003

Silencing of a specific mRNA using double stranded RNA oligonucleotides represents one of the newest technologies for suppressing a specific gene product. Small interfering RNA (siRNA) are 21 nucleotides long, double stranded RNA fragments that are identical in sequence to the target mRNA. We designed 3 such siRNA against the Her2/neu (HER2) gene. The HER2 gene is known to play an important role in the oncogenesis of several types of cancers, such as breast, ovarian, colon and gastric cancers. Introduction of the siRNA into HER2 positive tumor lines in vitro greatly reduced the cell surface expression of the HER2 protein. Concurrently, a range of effects on cell physiology, such as growth i…

Cancer Researchmedicine.medical_specialtySmall interfering RNAApoptosisBreast NeoplasmsAntibodies Monoclonal HumanizedTransfectionHER2/neuGene productRNA interferenceInternal medicineCell Line TumormedicineGene silencingHumansGene SilencingRNA Small Interferingskin and connective tissue diseasesneoplasmsOvarian NeoplasmsMessenger RNAbiologyHistocompatibility Antigens Class IRNAAntibodies MonoclonalTransfectionGenes erbB-2TrastuzumabUp-RegulationEndocrinologyOncologyCancer researchbiology.proteinFemaleInternational journal of cancer
researchProduct

Cellular immunity to the Her-2/neu protooncogene

2002

Her-2/neu (HER-2) is a 185-kDa receptor-like glycoprotein that is overexpressed by a variety of tumors such as breast, ovarian, gastric, and colorectal carcinomas. Overexpression of this oncogene is directly associated with malignant transformation of epithelial cells. The frequency of HER-2 overexpression varies among the different types of cancers, but universally represents a marker of poor prognosis. The critical role of HER-2 in epithelial oncogenesis as well as its selective overexpression on malignant tissues makes it an ideal target for immunotherapy. Antibodies and T cells reactive to HER-2 are known to naturally occur in patients with HER-2 positive tumors, confirming the immunoge…

Cellular immunitymedicine.drug_classbusiness.industryT cellmedicine.medical_treatmentImmunotherapyMonoclonal antibodymedicine.anatomical_structureImmune systemAntigenTrastuzumabImmunologyMonoclonalmedicinebusinessmedicine.drug
researchProduct